HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 1101042

Also Known As:

runcaciguat

Networked: 4 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        BAY 1101042: 4
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        BAY 1101042: 4

Experts

1.	Hahn, Michael G: 3 articles (12/2021 - 01/2021)
2.	Sandner, Peter: 3 articles (12/2021 - 01/2021)
3.	Stasch, Johannes-Peter: 3 articles (12/2021 - 01/2021)
4.	Eitner, Frank: 2 articles (12/2021 - 01/2021)
5.	Hueser, Joerg: 2 articles (12/2021 - 01/2021)
6.	Schomber, Tibor: 2 articles (12/2021 - 01/2021)
7.	Bénardeau, Agnès: 1 article (12/2021)
8.	Hartmann, Elke: 1 article (12/2021)
9.	Kahnert, Antje: 1 article (12/2021)
10.	Kraehling, Jan R: 1 article (12/2021)

Related Diseases

1.	Chronic Renal Insufficiency 01/01/2021 - "Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy." 12/01/2021 - "Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease." 10/02/2021 - "Substantial research efforts improved on the first-generation sGC activators such as cinaciguat, culminating in the discovery of runcaciguat, currently in clinical Phase II trials for chronic kidney disease and diabetic retinopathy. " 08/25/2023 - "Chronic kidney disease (CKD) progression is associated with persisting oxidative stress, which impairs the NO-sGC-cGMP signaling cascade through the formation of oxidized and heme-free apo-sGC that cannot be activated by NO. Runcaciguat (BAY 1101042) is a novel, potent, and selective sGC activator that binds and activates oxidized and heme-free sGC and thereby restores NO-sGC-cGMP signaling under oxidative stress. "
2.	Diabetic Retinopathy (Retinopathy, Diabetic) 01/01/2021 - "Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy." 10/02/2021 - "Substantial research efforts improved on the first-generation sGC activators such as cinaciguat, culminating in the discovery of runcaciguat, currently in clinical Phase II trials for chronic kidney disease and diabetic retinopathy. "
3.	Obesity 08/25/2023 - "The potential kidney-protective effects of runcaciguat were investigated in ZSF1 rats as a model of CKD/DKD, characterized by hypertension, hyperglycemia, obesity, and insulin resistance. "
4.	Insulin Resistance 08/25/2023 - "The potential kidney-protective effects of runcaciguat were investigated in ZSF1 rats as a model of CKD/DKD, characterized by hypertension, hyperglycemia, obesity, and insulin resistance. "
5.	Hypertension (High Blood Pressure) 08/25/2023 - "The potential kidney-protective effects of runcaciguat were investigated in ZSF1 rats as a model of CKD/DKD, characterized by hypertension, hyperglycemia, obesity, and insulin resistance. "

Related Drugs and Biologics

1.	BAY 58-2667
2.	Biomarkers (Surrogate Marker)
3.	BAY 1101042
4.	Proteins (Proteins, Gene)
5.	Heme (Haem)
6.	Creatinine
7.	Soluble Guanylyl Cyclase